BRCA2 and neoplasm: The recurrent onco-suppressors genes involved in uLMS including BRCA2, coupled with the frequent inactivation of genes implicated in DNA damage and homologous recombination repair, further depict this disease as a tumor with defects in proper DNA repair and reinforce the role of PARP inhibitors in the treatment of uLMS [31].